Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CRBP | PRESS-RELEASE | neutral | 4/10 | Corbus reported Q1 2026 net loss of $23.0M ($1.23/share), slightly missing consensus EPS of -$1.22. The company highligh | May 12, 2026 |
| RYTM | PRESS-RELEASE | neutral | 4/10 | Rhythm Pharmaceuticals presented positive clinical data for setmelanotide at ECE 2026, including significant BMI reducti | May 12, 2026 |
| TENX | 8-K | neutral | 4/10 | Tenax Therapeutics reported Q1 2026 EPS of -$0.35, beating consensus of -$0.40 by 12.5%, though net loss widened to $15. | May 12, 2026 |
| PMVP | 8-K | neutral | 3/10 | PMV Pharma reported Q1 2026 net loss per share of -$0.34, in line with the year-ago period and beating consensus estimat | May 12, 2026 |
| UNCY | 8-K | neutral | 4/10 | Unicycive Therapeutics reported Q1 2026 results with an EPS of -$0.54, slightly beating the consensus of -$0.55. The com | May 12, 2026 |
| VTGN | 8-K | neutral | 4/10 | Vistagen announced preliminary positive safety and exploratory efficacy data from the open-label extension (OLE) of its | May 12, 2026 |
| INKT | PRESS-RELEASE | bullish | 7/10 | MiNK Therapeutics presented data at ASGCT 2026 showing its off-the-shelf iNKT cell therapy, agenT-797, produced context- | May 12, 2026 |
| SGMT | 8-K | neutral | 5/10 | Sagimet Biosciences reported Q1 2026 net loss of $10.7M ($0.33/share), narrower than the $18.2M loss in Q1 2025, with ca | May 12, 2026 |
| XLO | 8-K | neutral | 4/10 | Xilio Therapeutics reported Q1 2026 collaboration and license revenue of $12.6M (up from $2.9M YoY) and a net loss of $9 | May 12, 2026 |
| HBIO | 8-K | mixed | 5/10 | Harvard Bioscience filed an 8-K with an investor presentation providing FY26 guidance of 2-4% revenue growth and 6-10% a | May 12, 2026 |
| COLL | PRESS-RELEASE | bullish | 7/10 | Collegium Pharmaceutical completed the acquisition of AZSTARYS, an ADHD treatment, from Corium Therapeutics for $650 mil | May 12, 2026 |
| IXHL | 8-K | neutral | 2/10 | Incannex Healthcare announced it won the 'Best New Technology Solution for Drug Development' award at the 10th annual Me | May 12, 2026 |
| HBIO | PRESS-RELEASE | neutral | 4/10 | Harvard Bioscience reported Q1 2026 revenue of $20.8M, down 4.6% YoY from $21.8M, and a GAAP net loss of $(3.4)M, improv | May 12, 2026 |
| SABS | PRESS-RELEASE | bearish | 7/10 | SAB Biotherapeutics reported Q1 2026 EPS of -$0.35, a 68.3% miss vs consensus of -$0.21, with net loss widening to $18.9 | May 12, 2026 |
| MREO | PRESS-RELEASE | bearish | 6/10 | Mereo BioPharma reported Q1 2026 EPS of -$0.01, missing the $0.00 consensus estimate, with revenue not explicitly stated | May 12, 2026 |
| XLO | PRESS-RELEASE | bullish | 7/10 | Xilio Therapeutics reported Q1 2026 results with collaboration revenue of $12.6M (up from $2.9M a year ago) and a net lo | May 12, 2026 |
| SGMT | PRESS-RELEASE | mixed | 6/10 | Sagimet Biosciences reported Q1 2026 EPS of -$0.33 (GAAP), beating consensus of -$0.35, with net loss narrowing to $10.7 | May 12, 2026 |
| BBIO | PRESS-RELEASE | bullish | 8/10 | BridgeBio announced NDA submission to the FDA for encaleret in ADH1, supported by positive Phase 3 CALIBRATE data showin | May 12, 2026 |
| HBIO | 8-K | bearish | 6/10 | Harvard Bioscience reported Q1 2026 revenue of $20.8M, down 4.7% YoY from $21.8M, and a GAAP net loss of $(3.4M) vs $(50 | May 12, 2026 |
| VREOF | 8-K | bearish | 7/10 | Vireo Growth Inc. reported Q1 2026 GAAP revenue of $106.2M, up 333.5% YoY, but driven entirely by M&A (Schwazze, Eaze, H | May 12, 2026 |
| ACHV | 8-K | mixed | 7/10 | Achieve Life Sciences reported Q1 2026 net loss of $10.2M ($0.19/share) vs $12.8M ($0.37/share) in Q1 2025, with operati | May 12, 2026 |
| ARVN | 8-K | mixed | 6/10 | Arvinas reported Q1 2026 revenue of $15.6M, a 91.7% decline from $188.8M in Q1 2025, driven by the completion of large m | May 12, 2026 |
| ARVN | 8-K | bullish | 7/10 | Arvinas and Pfizer entered into a license agreement with Rigel Pharmaceuticals for exclusive global rights to VEPPANU (v | May 12, 2026 |
| PRLD | 8-K | bullish | 6/10 | Prelude Therapeutics reported Q1 2026 results with a net loss of $0.13 per share, significantly narrower than the $0.42 | May 12, 2026 |
| ALKS | 8-K | bullish | 7/10 | Alkermes announced positive topline results from the REVITALYZ Phase 3 study of LUMRYZ in idiopathic hypersomnia (IH), m | May 12, 2026 |
| IMTX | 6-K | bearish | 6/10 | Immatics reported Q1 2026 financial results showing a net loss of €57.8 million ($66.5 million) on revenue of €7.6 milli | May 12, 2026 |
| LEGN | 6-K | bullish | 7/10 | Legend Biotech reported Q1 2026 results with total revenue of $305.1M, up 56% YoY from $195.0M, driven by a 61% increase | May 12, 2026 |
| SION | 8-K | neutral | 5/10 | Sionna Therapeutics reported Q1 2026 financial results with a net loss of $26.8M ($-0.60/share), wider than the $16.5M l | May 12, 2026 |
| ABOS | 8-K | neutral | 3/10 | Acumen Pharmaceuticals reported Q1 2026 results with a net loss of $20.7M ($0.33/share), narrower than the $28.8M loss ( | May 12, 2026 |
| PRQR | 6-K | bearish | 6/10 | ProQR reported Q1 2026 results with revenue declining 55% YoY to €2.0M and net loss widening 33% to €13.4M (€0.13/share) | May 12, 2026 |